Cardiac Glycosides as Senolytic Compounds

Nadine Martin; Olivier Soriani; David Bernard

doi:10.1016/j.molmed.2020.01.001

Cardiac Glycosides as Senolytic Compounds

Trends Mol Med. 2020 Mar;26(3):243-245. doi: 10.1016/j.molmed.2020.01.001. Epub 2020 Jan 23.

Authors

Nadine Martin¹, Olivier Soriani², David Bernard³

Affiliations

¹ Centre de Recherche en Cancérologie de Lyon, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 1052, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche 5286, Université de Lyon, Centre Léon Bérard, Lyon, France. Electronic address: nadine.martin@lyon.unicancer.fr.
² INSERM, CNRS, Institut de Biologie Valrose (iBV), Université Côte d'Azur, Nice, France.
³ Centre de Recherche en Cancérologie de Lyon, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 1052, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche 5286, Université de Lyon, Centre Léon Bérard, Lyon, France. Electronic address: david.bernard@lyon.unicancer.fr.

PMID: 31983612
DOI: 10.1016/j.molmed.2020.01.001

Abstract

The identification of senolytics, compounds that eliminate senescent cells, is presently a key priority given their therapeutic promise in cancer and aging-associated diseases. Two recent papers by Triana-Martínez et al. and Guerrero et al. report the senolytic activity of cardiac glycosides (CGs) and their efficacy in these pathophysiological contexts.

Keywords: aging; cancer; cardiac glycosides; cellular senescence; senolytics.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aging / drug effects*
Cardiac Glycosides / therapeutic use*
Cellular Senescence / drug effects
Humans
Neoplasms / drug therapy*

Substances

Cardiac Glycosides